Nuwellis receives USPTO allowance for innovative dual lumen midline catheter technology.

Nuwellis, Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its new dual lumen midline catheter technology designed for ultrafiltration therapies. This catheter features advanced design elements to optimize blood flow and reduce complications, including separate lumens for withdrawal and infusion, pressure-balancing features, and customizable length with kink resistance. The patent supports Nuwellis' strategy to enhance its Aquadex SmartFlow system and expand ultrafiltration therapy access in hospitals and outpatient settings. This innovation aims to improve patient outcomes and clinician experience in managing cardiorenal conditions.